how to play haha777
how to play haha777
TikTok is inching closer to a potential ban in the US. So what's next?
Trump says he can't guarantee tariffs won't raise US prices and won't rule out revenge prosecutionsFortinet Launches FortiAppSec Cloud to Strengthen Web Security
American and European stock markets mostly rose on Wednesday after inflation data cemented expectations that the US Federal Reserve will trim interest rates next month. While the Dow fell slightly, the other two major US indices advanced, led by the tech-rich Nasdaq, which piled on almost two percent to close above 20,000 points for the first time. The consumer price index (CPI) rose to 2.7 percent last month from a year ago, up slightly from 2.6 percent in October. "With the CPI numbers broadly in line, it is likely that the Fed will not be derailed and will cut rates again next week," Jochen Stanzl, chief market analyst at CMC Markets. "The data is not a showstopper for the current bull run on Wall Street," he added. Ahead of the data, investors priced in an 86 percent chance the Fed will cut interest rates next week by a quarter percentage point. That rose to more than 98 percent after the CPI data was published. Stocks in Paris and Frankfurt rose ahead of the European Central Bank's own interest rate announcement on Thursday, with analysts expecting another cut as it seeks to boost eurozone growth. Investors are also eyeing political developments in France, where officials said President Emmanuel Macron aims to name a new prime minister "within 48 hours" as he seeks to end political deadlock following the ouster of Michel Barnier. In company news, shares in German retail giant Zalando shed more than four percent on Frankfurt's DAX index, after it acquired domestic rival About You in a deal worth around 1.1 billion euros ($1.2 billion). Shares in Zara owner Inditex slid more than six percent after a record quarterly profit for the group fell short of market estimates. Among US companies, Google parent Alphabet earned 5.5 percent as it announced the launch of Gemini 2.0, its most advanced artificial intelligence model to date. That added to gains after Google also announced Tuesday details of a breakthrough quantum chip. Shares in Shanghai rose but Hong Kong gave up an early rally to end in the red. Traders were keeping tabs on China to see if it will announce further measures to support its struggling economy as leaders were to gather Wednesday for a conference to hammer out next year's agenda. President Xi Jinping and other top leaders on Monday announced their first major shift in policy for more than a decade, saying they would "implement a more active fiscal policy and an appropriately relaxed" strategy. Those remarks sparked hopes for more interest rate cuts and the freeing up of more cash for lending. New York - Dow: DOWN 0.2 percent at 44,148.56 (close) New York - S&P 500: UP 0.8 percent at 6,084.19 (close) New York - Nasdaq Composite: UP 1.8 percent at 20,034.89 (close) London - FTSE 100: UP 0.3 percent at 8,301.62 (close) Paris - CAC 40: UP 0.4 percent at 7,423.40 (close) Frankfurt - DAX: UP 0.3 percent at 20,399.16 (close) Tokyo - Nikkei 225: FLAT at 39,372.23 (close) Hong Kong - Hang Seng Index: DOWN 0.8 percent at 20,155.05 (close) Shanghai - Composite: UP 0.3 percent at 3,432.49 (close) Euro/dollar: DOWN at $1.0498 from $1.0527 on Tuesday Pound/dollar: DOWN at $1.2752 from $1.2771 Dollar/yen: UP at 152.40 yen from 151.95 yen Euro/pound: DOWN at 82.31 from 82.42 pence Brent North Sea Crude: UP 1.8 percent at $73.52 per barrel West Texas Intermediate: UP 2.4 percent at $70.29 per barrel burs-jmb/mlmWilly Adames agrees to $182 million, 7-year deal with the Giants, AP source says Willy Adames has agreed to a $182 million, seven-year deal with San Francisco, providing the Giants with a power-hitting shortstop in the prime of his career, according to a person familiar with the negotiations. The person spoke to The Associated Press on condition of anonymity because the agreement was pending a physical. ESPN first reported the move. The 29-year-old Adames is coming off his best offensive season in the big leagues after hitting .251 with a career-high 32 homers and 112 RBIs with the Milwaukee Brewers. Georgia QB Carson Beck knocked out by hand injury in SEC championship game against Texas ATLANTA (AP) — Georgia quarterback Carson Beck will not return after he was hit on his throwing hand on the final play of an ugly first half in the Southeastern Conference championship game against Texas. Beck was hit by outside linebacker Trey Moore, forcing a fumble recovered by Anthony Hill Jr., who then lost the ball on an errant attempt to extend the play with a lateral as time expired. Beck was one of the last players to return to the field following halftime. Backup Gunner Stockton led the offense to a touchdown on the Bulldogs’ first drive of the second half. Arizona State makes College Football Playoff with 45-19 win over Iowa State in Big 12 title game ARLINGTON, Texas (AP) — Big 12 newcomer Arizona State will represent the conference in the 12-team College Football Playoff. Cam Skattebo ran for 170 yards and two scores while adding a touchdown catch the 12th-ranked Sun Devils beat No. 16 Iowa State 45-19 in the Big 12 championship game. The Sun Devils with 34-year-old head coach Kenny Dillingham are 11-2 after being the preseason pick to finish at the bottom of their new 16-team league. They have won six games in a row. Iowa State is 10-3, already the first 10-win season in the program's 133-year history. LA Galaxy strike early, hold off New York Red Bulls 2-1 to win their record 6th MLS Cup championship CARSON, Calif. (AP) — Joseph Paintsil and Dejan Joveljic scored in the first half, and the LA Galaxy won their record sixth MLS Cup championship with a 2-1 victory over the New York Red Bulls. After striking twice in the first 13 minutes with goals from their star forwards, the Galaxy nursed a lead through a scoreless second half to raise their league’s biggest trophy for the first time since 2014. Sean Nealis scored for the seventh-seeded Red Bulls, whose improbable charge through the playoffs ended one win shy of the founding MLS franchise’s first Cup championship. No. 16 Iowa State falls short in Big 12 title game again, this time with CFP at stake ARLINGTON, Texas (AP) — The stakes were higher for Iowa State, and the outcome was the same as the first for the Cyclones in their second trip to the Big 12 championship game. And the 112-year wait for a conference title will go on. No. 16 Iowa State was playing for a spot in the expanded 12-team College Football Playoff in a 45-19 loss to 12th-ranked Arizona State. Four years ago, neither Iowa State nor Oklahoma had a realistic path into the four-team tournament before the Sooners' 27-21 victory. The Cyclones haven't won a conference title since going 2-0 in the Missouri Valley Intercollegiate Athletic Association in 1912. Big 12's Yormark brings up hard choices for fans before sparsely attended title game ARLINGTON, Texas (AP) — College football fans are facing some hard choices in the expanded playoff system with some teams set to play away from home multiple times. Big 12 Commissioner Brett Yormark raised that point No. 12 Arizona State's 45-19 victory over 16th-ranked Iowa State. The announced crowd of 55,889 at the home of the Dallas Cowboys appeared far smaller. Yormark says he remains committed to having a Big 12 title game. Besides the issues of fans, there have been suggestions that some leagues might be better off without title games as it relates to playoff hopes. Lindsey Vonn competes in a pair of downhills, another step on her comeback trail at the age of 40 COPPER MOUNTAIN, Colo. (AP) — Lindsey Vonn finished in the middle of the pack in a pair of lower-level downhill events as she competed for the first time in nearly six years. The 40-year-old Vonn is on the comeback trail after stepping away from the sport because of injuries. Vonn wasn't concerned with times and places in the races so much as getting used to the speed again and gaining the necessary points to compete on the World Cup circuit. Vonn accomplished both, finishing 24th in the first downhill race of the day and 27th in the second. She posted on social media after the FIS races she had enough points to enter World Cup events. Justin Thomas with big drives and a few big putts takes 1-shot lead over Scheffler in the Bahamas NASSAU, Bahamas (AP) — Justin Thomas has a one-shot lead over Scottie Scheffler going into the final round of the Hero World Challenge in the Bahamas. Thomas is using a slightly longer driver and has been blasting away. He also was helped by two long putts on the back nine that carried him to 66 at windy Albany Golf Club. Scheffler muffed a chip on the 13th hole that cost him the lead and he never caught up. He still shot a 69 and will be in the last group with Thomas on Sunday. Tom Kim had a 62 and was two shots back. Oklahoma State coach Mike Gundy gets restructured deal after 3-9 season, according to reports Oklahoma State football coach Mike Gundy will be staying on with a restructured deal. That's according to news reports published on Saturday. The deal reportedly will shift some of his salary to revenue sharing with players. The Cowboys were among the preseason favorites in the Big 12, but a rash of injuries and problems at quarterback tanked the team, and the Cowboys went 3-9. The school's Board of Regents held a special meeting on Friday morning regarding his status, but no immediate action was taken. The fact that Gundy has 169 wins in 20 years plus a hefty buyout likely saved him from being fired outright. Norris takes pole for season-ending Abu Dhabi GP and Hamilton 18th in Mercedes farewell ABU DHABI, United Arab Emirates (AP) — Lando Norris took pole position for the last Formula 1 race of the season alongside teammate Oscar Piastri to put McLaren on the verge of a first constructors’ title in 26 years. Norris’ last lap put him .209 of a second faster than Piastri, with Ferrari’s Carlos Sainz Jr. .020 further back. Seven-time F1 champion Hamilton qualified 18th for his last race with Mercedes after a bizarre incident wrecked his final qualifying lap. A plastic pole marking the inside of a corner was knocked loose by Kevin Magnussen’s Haas and Hamilton drove over it.
T-cell malignancies account for about 10-15% of all lymphoid malignancies, and their treatment often involves chemotherapy, immunotherapy, or stem cell transplantation. These cancers can be particularly challenging due to their heterogeneity and resistance to traditional treatments. LAS VEGAS , Dec. 11, 2024 /PRNewswire/ -- T-cell malignancies are a group of cancers originating from the T-cells, a vital part of the immune system responsible for recognizing and combating foreign invaders. These cancers can develop when T-cells undergo genetic mutations, leading to uncontrolled growth and division. T-cell malignancies are generally categorized into two broad types: T-cell lymphomas and T-cell leukemias. T-cell lymphomas primarily affect the lymphatic system, involving lymph nodes and other lymphoid tissues, while T-cell leukemias impact the blood and bone marrow. These malignancies are often more aggressive and harder to treat than B-cell cancers due to their complex biology and resistance to conventional therapies. Symptoms can vary but typically include enlarged lymph nodes, fever, night sweats, and weight loss. Treatment options include chemotherapy, radiation therapy, and novel therapies like CAR T-cell therapy and targeted therapies, which are advancing the understanding and management of these challenging cancers. DelveInsight has recently released a series of epidemiology-based market reports focusing on T-cell malignancies including Acute Lymphoblastic Leukemia, Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Adult T-cell Leukemia/Lymphoma . These reports include a comprehensive understanding of current treatment practices, historical and forecasted patient pool, emerging drugs, market share of individual therapies, and historical and forecasted market size from 2020 to 2034 segmented into 7MM [ the United States , the EU-4 ( Italy , Spain , France , and Germany ), the United Kingdom , and Japan ]. Additionally, the reports feature exhaustive analysis of prominent companies working with their emerging candidates in different stages of clinical development. Let's deep dive into the assessment of these T-cell malignancies markets individually. Acute Lymphocytic Leukemia Market Acute lymphocytic leukemia (ALL), also called acute lymphoblastic leukemia, is a cancer that develops in the blood and bone marrow. It originates from immature white blood cells known as lymphocytes in the bone marrow and is marked by the excessive production of immature cells, referred to as lymphoblasts or leukemic blasts. As the bone marrow fails to produce sufficient red blood cells, healthy white blood cells, and platelets, individuals with ALL are more prone to anemia, frequent infections, and easy bruising or bleeding. Among the 7MM, the US accounted for the highest number of incident cases of acute lymphocytic leukemia. The total incident cases of acute lymphocytic leukemia in the US comprised approximately 6,800 cases in 2023 and are projected to increase during the forecast period. Among the type-specific cases of acute lymphocytic leukemia, B-acute lymphocytic leukemia accounted for nearly 85% of the cases, while T-acute lymphocytic leukemia accounted for nearly 15% in the US. The treatment paradigms of acute lymphocytic leukemia have been revolutionized with the advent of tyrosine kinase inhibitors targeting BCR-ABL1 (GLEEVEC [imatinib mesylate], SPRYCEL [dasatinib], and ICLUSIG [ponatinib]), monoclonal antibodies targeting CD20 (RITUXAN), antibody-drug conjugates targeting CD22 (BESPONSA), bispecific antibodies (BLINCYTO), CD19 chimeric antigen receptor T cell therapy (KYMRIAH and TECARTUS) , and others. As per DelveInsight analysis, in 2023, the market size for acute lymphocytic leukemia across the 7MM was around USD 1.6 billion , with projections indicating further growth by 2034. The United States dominated the market in 2023, contributing approximately USD 1.2 billion . ALL presents a significant market opportunity, with BLINCYTO currently leading the segment. Amgen continues to drive innovation in ALL through its BiTE Technology, receiving FDA approval in June 2024 . Additionally, Amgen is advancing a registration-enabling study to develop a subcutaneous injection formulation of blinatumomab. Acute Lymphocytic Leukemia Pipeline Therapies and Companies Orca-T: Orca Biosystems AUTO1/22: Autolus Therapeutics VENCLEXTA/VENCLYXTO (venetoclax): AbbVie and Roche (Genentech) Daratumumab: J&J Innovative Medicine IMBRUVICA (ibrutinib): Pharmacyclics (an AbbVie Company) JAKAFI (ruxolitinib): Incyte Corporation/Novartis VYXEOS (CPX-351): Jazz Pharmaceuticals Obecabtagene autoleucel (obe-cel): Autolus Therapeutics SNDX-5613 (revumenib): Syndax Pharmaceuticals UCART22: Cellectis ADCT-602: ADC Therapeutics WU-CART-007: Wugen For a comprehensive view of the acute lymphocytic leukemia market, check out the Acute Lymphocytic Leukemia Market Assessment Peripheral T-cell Lymphoma Market Peripheral T-cell lymphoma represents a heterogeneous collection of aggressive lymphomas arising from mature T-cells and natural killer cells, comprising approximately 10–15% of all non-Hodgkin lymphomas globally. PTCL is more prevalent in Asia compared to North America and Europe . PTCL has been reported to account for 25% of all NHL cases in Japan . The increased rate of T-cell lymphomas in Asia is attributed to the low incidence of follicular lymphomas. The total incident cases of PTCL in the 7MM were 26,000 cases in 2023; these cases are estimated to increase by 2034. As more targetable mutations are identified and new targeted therapies are developed, the range of treatment options for patients and oncologists continues to expand. However, with the rapid pace of drug approvals, it is crucial to ensure that adequate supporting data justifies the use of specific therapies in the appropriate treatment settings, whether as adjuvant, consolidation, first-line, or subsequent treatments. Peripheral T-cell lymphoma remains a significant therapeutic challenge due to its aggressive nature, rarity, and high heterogeneity. Conventional chemotherapy for PTCL typically involves anthracycline-based regimens (such as CHOP and EPOCH) or non-anthracycline alternatives (including platinum, etoposide, gemcitabine, and methylprednisolone). While the majority of patients initially undergo chemotherapy, nearly a quarter develop primary refractory disease. Many others relapse even after responding to induction chemotherapy, with a median overall survival of just six months. According to NCCN guidelines, specific PTCL subtypes are also treated with six cycles of CHOP-21 or CHOEP, often combined with involved-site radiation therapy. The FDA has approved several drugs for PTCL treatment, including BELEODAQ (Belinostat, Acrotech Biopharma), ISTODAX (Romidepsin, Celgene), FOLOTYN (Pralatrexate, Acrotech Biopharma), ARRANON (Nelarabine, GlaxoSmithKline), XALKORI (Crizotinib, Pfizer), and ADCETRIS (Brentuximab Vedotin, Seattle Genetics). Until recently, there was no established standard of care for first-line treatment in PTCL, leaving a significant gap in approved therapies. The approval of ADCETRIS in November 2018 by the US FDA has transformed the treatment landscape. ADCETRIS, in combination with chemotherapy, is now the first and only FDA-approved regimen for first-line treatment of adults with previously untreated systemic ALCL or other CD30-expressing PTCL. Notably, its approval came less than two weeks after submission under the FDA's real-time oncology review pilot program. Key players, such as Secura Bio, HUYA Bioscience International, Verastem, Solasia Pharma, Seagen, Dizal Pharmaceutical , and others, are evaluating their lead candidates in different stages of clinical development, respectively. As per the DelveInsight assessment, the total market size in the 7MM for PTCL was estimated to be ~USD 680 million in 2020, which is projected to show positive growth by 2034. This growth of the PTCL market is expected to be mainly driven by increased diagnosed incidence, patient awareness, and a robust clinical pipeline during the forecast period (2024–2034). PTCL Pipeline Therapies and Companies COPIKTRA (duvelisib): Secura Bio Linperlisib (YY-20394): Shanghai YingLi Pharmaceutical Golidocitinib (DZD4205) : Dizal Pharmaceuticals Nanatinostat + Valganciclovir: Viracta Therapeutics Lacutamab/IPH4102: Innate Pharma Sugemalimab (CS1001): CStone Pharmaceuticals AFM13: Affimed Tolinapant (ASTX660): Otsuka Pharmaceutical/Astex Pharmaceuticals AUTO4: Autolus MT-101: Myeloid Therapeutics KEYTRUDA (pembrolizumab): Merck Sharp & Dohme OPDIVO (nivolumab): Bristol Myers Squibb To gain a deeper understanding of the PTCL market, be sure to explore the Peripheral T-cell Lymphoma Market Outlook Cutaneous T-cell Lymphoma Market Cutaneous T-cell lymphomas are rare cancers that predominantly involve the skin. Some types progress slowly within the skin, while others may spread to the blood or lymph nodes. The most prevalent form of CTCL is mycosis fungoides, along with its leukemic variant, Sézary syndrome. Another frequently encountered group includes CD30-positive lymphoproliferative disorders (CD30+ LPDs). In 7MM, the United States accounted for the highest number of incident cases of CTCL, which is 46% of the total incident population of CTCL in 7MM in 2023, as per DelveInsight. In the US, out of all stage-specific cases of CTCL, Stage-IA accounted for the highest number of cases, followed by Stage-IB and Stage-IIB cases in 2023. There is currently no approved first-line therapy for early-stage (I–IIA) cutaneous T-cell lymphoma, highlighting a significant unmet need in this patient population. Treatment decisions for patients with mycosis fungoides and Sézary syndrome, both types of CTCL, are influenced by factors such as the extent of skin involvement, the type of lesions, and whether metastasis is present. Therapies for mycosis fungoides focus on either localized skin treatment or systemic approaches, allowing many patients to achieve long-term remission and maintain normal lives. In contrast, Sézary syndrome, marked by systemic involvement, often requires systemic therapies, either alone or in combination, to improve long-term outcomes. TARGRETIN, ADCETRIS, POTELIGEO, ZOLINZA, and ISTODAX are approved by the US FDA for the treatment of Mycosis Fungoides and Sezary Syndrome. Other systemic therapies such as interferons (alfa and gamma), methotrexate, and other retinoids (acitretin and isotretinoin) also offer clinical benefits but have only been evaluated in small studies. As per DelveInsight analysis, the market size of CTCL in the 7MM is expected to cross USD 780 million by 2034. This growth is mainly driven by advancements in targeted therapies, rising awareness of rare cancers, and increasing research and development investments. The adoption of innovative treatments such as monoclonal antibodies and checkpoint inhibitors, coupled with improved diagnostic technologies, is anticipated to enhance market expansion. Additionally, a growing patient population and supportive regulatory policies will further bolster market growth. CTCL Pipeline Therapies and Companies HyBryte (SGX301): Soligenix KINSELBY (resminostat): 4SC AG Lacutamab: Innate Pharma Explore in-depth for a comprehensive understanding of the Cutaneous T-cell Lymphoma Clinical Trials Anaplastic Large Cell Lymphoma Market Anaplastic large cell lymphoma (ALCL) is a rare subtype of non-Hodgkin lymphoma, characterized by large, irregular lymphoid cells that express the CD30 antigen. ALCL accounts for approximately 1% of all NHL cases and 16% of T-cell lymphomas. ALK-positive ALCL is associated with conditions such as HIV, mycosis fungoides, and pulmonary or inflammatory pseudotumors. In contrast, ALK-negative ALCL is more commonly observed in older individuals and is frequently linked to extranodal disease involvement. As per DelveInsight's analysis, ALCL has a slightly higher incidence in men compared to women. ALK-positive ALCL typically affects children and adolescents, with a median age of 30 years, while ALK-negative ALCL tends to affect older adults, with a median age of 54 years. ALK-positive ALCL carries a better prognosis, with 5-year survival rates of 70% to 90% , compared to 40% to 60% for ALK-negative ALCL. The treatment of ALCL varies based on its subtype and stage. Systemic ALCL is commonly addressed with chemotherapy regimens such as CHOP or CHOEP, showing improved outcomes in ALK-positive cases. The key drugs used for the treatment of anaplastic large cell lymphoma are – Pfizer's XALKORI and Takeda's ADCETRIS. For relapsed or refractory cases, brentuximab vedotin has proven effective. Primary cutaneous ALCL is typically managed through radiation, surgery, or chemotherapy and generally has a good prognosis. Breast implant-associated ALCL is treated by removing the implant, with radiation or chemotherapy added if the disease has spread. The ALCL market is anticipated to witness a substantial positive shift owing to better uptake of existing drugs, the expected market launch of therapies, and raised awareness. Additionally, the ALCL market size is expected to increase due to an increasing diagnosed prevalent population, awareness about the subtype of ALCL (Breast implant-associated ALCL), and an increase in R&D activity, which would essentially boost the commercial success of emerging therapies. Anaplastic Large Cell Lymphoma Pipeline Therapies and Companies AUTO4: Autolus Therapeutics SGN-35T: Seagen To access a complete analysis of the anaplastic large cell lymphoma market, visit Anaplastic Large Cell Lymphoma Market Assessment Adult T-cell Leukemia/Lymphoma Market Adult T-cell Leukemia/Lymphoma (ATLL) is a rare and aggressive malignancy of mature T lymphocytes caused by infection with the human T-cell lymphotropic virus type 1 (HTLV-1). ATLL is classified into four clinical subtypes: acute, lymphomatous, chronic, and smoldering, each with distinct prognoses. The acute and lymphomatous forms are the most aggressive, with a median survival of less than a year without treatment. ATLL commonly affects adults aged 40–60 years and is associated with immunosuppression, hypercalcemia, and frequent involvement of skin, lymph nodes, and bone marrow. The global prevalence varies, but it is estimated that about 5–10% of individuals infected with HTLV-1 develop ATLL after decades of latency. Treatment for ATLL is challenging, as the disease presents with a wide range of clinical manifestations, from chronic to acute forms. First-line therapy often involves combination chemotherapy regimens, such as the CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone) regimen, which has shown effectiveness in treating the aggressive forms of ATLL. For more refractory or relapsed cases, a bone marrow transplant may be considered as a curative option. Additionally, the use of denileukin diftitox, a fusion protein targeting CD25, has been approved for relapsed or refractory ATLL. Newer therapies are exploring the use of targeted agents, including histone deacetylase inhibitors (e.g., romidepsin) and lenalidomide, a potent immune-modulatory drug, to improve outcomes in patients with advanced disease. However, despite these options, ATLL treatment remains an area in urgent need of innovation to improve survival rates and quality of life for patients. The Adult T-cell leukemia/lymphoma market is expected to witness significant growth in the coming years, driven by advancements in diagnostics, therapies, and an increased understanding of the disease. Additionally, innovations in immunotherapies, including monoclonal antibodies, CAR-T cell therapies, and combination regimens, are expected to revolutionize the treatment landscape, offering hope for improved survival rates. Moreover, ongoing research into biomarkers and precision medicine will likely lead to better patient stratification and more effective treatment plans. Overall, the ATLL market is poised for expansion, attracting investments in research and development, clinical trials, and regulatory approvals to meet the growing need for better, more accessible therapies. Adult T-cell Leukemia/Lymphoma Pipeline Therapies and Companies Valemetostat Tosylate: Daiichi Sankyo BEAM-201: Beam Therapeutics Inc. Tolinapant: Astex Pharmaceuticals To delve into the adult T-cell leukemia/lymphoma market landscape in more detail, access the Adult T-cell Leukemia/Lymphoma Market Report Trending Oncology Reports Non-Hodgkin Lymphoma Market Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Non-Hodgkin lymphoma companies, including Roche, Pfizer, Amgen, Novartis, Teva Pharmaceuticals, Genentech, ACD Therapeutics , among others. Non-Hodgkin Lymphoma Pipeline Non-Hodgkin Lymphoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key Non-Hodgkin lymphoma companies, including Roche, Pfizer, Amgen, Novartis, Teva Pharmaceuticals, Genentech, ACD Therapeutics , among others. B-Cell Lymphoma Market B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, among others. Diffuse Large B-Cell Lymphoma Market Diffuse Large B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including AbbVie, Genmab, Merck, Roche, Xencor and Janssen, Denovo Biopharma, Calithera Biosciences, IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 www.delveinsight.com Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg SOURCE DelveInsight Business Research, LLPNoneJamiya Neal finished with 19 points, nine rebounds, nine assists and four blocks to lead host Creighton over UNLV 83-65 on Saturday in Omaha, Neb. Creighton was without star Pop Isaacs, who was ruled out for the season on Saturday morning after undergoing surprise hip surgery. It was a startling turn, considering Isaacs led Creighton with 27 points in Wednesday's win over No. 1 Kansas. Neal and Steven Ashworth (17 points) anchored the backcourt in Isaacs' absence, combining to make 13-of-20 shots from the field. Neal made 7 of his 10 and Ashworth 6 of 10. Isaac Traudt also stepped up, making five 3-pointers off the bench to account for all 15 of his points. Ryan Kalkbrenner scored 12 points, making 4-of-5 attempts from the field, and added six rebounds. Creighton opened the second half on a 10-0 run, extending its lead to 49-27 before UNLV mustered an answer. Creighton made 10 consecutive shots early in the second half, extending its lead to a 62-41 with 12:20 remaining. Dedan Thomas Jr. paced UNLV with 18 points on 7-of-16 shooting, making 1 of 4 attempts from 3-point range. Jailen Bedford added a team-high 20 points for the Rebels on 8-of-15 shooting, scoring 17 points in the second half. Julian Rishwain added 10 points on 4-of-8 shooting, but UNLV's second leading scorer for the season, Jeremiah Cherry, was limited to just four points in 16 minutes after early foul trouble. Creighton shot a resounding 63.3 percent from the field for the game, including going 10-of-20 from beyond the arc. Creighton outscored UNLV 38-34 in the paint and outrebounded them 34-21. UNLV finished the game shooting 42.2 percent field, making 7-of-21 attempts from distance. --Field Level Media
Nasdaq surges above 20,000 after US inflation data matches estimates
Nation Mourns the Loss of Former PM Manmohan SinghPeople & Profit - One year of Milei's Argentina: Is 'shock therapy' working?Whitt scores 14, Belmont beats Middle Tennessee 82-79
Arizona tight end Keyan Burnett to enter transfer portalNone
Agilon Health director Wulf John William buys $98,145 in stock
